ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

PTC Therapeutics licenses Odylia’s gene-therapy technology

by Ryan Cross
July 5, 2019 | APPEARED IN VOLUME 97, ISSUE 27

 

PTC Therapeutics, a rare-disease drug company best known for small-molecule therapies that alter gene expression, is partnering with Odylia Therapeutics to develop gene therapies for inherited eye diseases. Odylia is a nonprofit founded in 2017 to launch clinical trials based on the dozens of preclinical studies suggesting gene therapies can partially restore vision in inherited forms of blindness. In the partnership, PTC will gain access to a class of adeno-associated viruses called Anc80, which were made in Luk H. Vandenberghe’s lab at Massachusetts Eye and Ear.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment